

Gut Microbiota Balance on Health–Disease

Subjects: Microbiology

Contributor: Luis González-Olivares

The gut microbiota is a group of organisms that provides various benefits and imparts resistance to the colonization of new species, maintaining a symbiotic relationship with the host. However, an imbalance in this complex community could lead to recolonization by pathogenic microorganisms, causing inflammatory processes and the evolution of various diseases . This suggests that gut microbiota maintains the homeostasis of the human intestine .

Keywords: microbiota ; microbiota–intestine–brain axis ; probiotic ; prebiotic

1. Introduction

The gut microbiota is a group of microorganisms that colonize the gastrointestinal tract, and is found in a higher proportion than the cells of the human body ^[1]. About half of the fecal mass constitutes the microorganisms that are essentially grouped into five phyla: Firmicutes, Bacteroidota, Verrucomicrobia, Actinobacteria, and Proteobacteria, with a 90% predominance of the first two ^[2]. Due to the diversity of microorganisms that makes them the most important environmental agent in the human body, various studies indicate that gut microbiota is directly associated with both the health of the host and some diseases ^[3]. Despite the evidence on the relationship of gut microbiota with the parameters of various diseases, more research is needed to evaluate other factors, such as the interaction between host genetics, diet, and metabolism regulation ^[4].

Once the microbiota is established in an individual, it usually changes in a short time, and the changes are even generated in stages during the life of the human. Notwithstanding its high variability, the alteration of gut microbiota composition has huge implications in the pathogenesis of a wide range of diseases, from chronic gastrointestinal diseases to neurological disorders. The influence of gut microbiota in the development of diseases is so great that some investigations have shown alterations in the serotonergic neurotransmission of the central nervous system (CNS), which were secondary to gut microbiota imbalance (dysbiosis) ^[5]. For this reason, enormous efforts have been directed to reverse the effect of intestinal dysbiosis in neurodegenerative diseases.

One of the main factors affecting the concentration changes over specific microorganisms of the gut microbiota is the combination of diet with genetic factors ^[6]. It explains why, in addition to gastrointestinal diseases, the microbiota has a direct effect on the development of diseases such as type 2 diabetes mellitus (DM2) and obesity, which are part of the so-called metabolic syndrome ^[7]. Additionally, dysbiosis has been presented as a risk factor in the development of various types of cancer, and, in addition to the genetic factor, abnormal microbial translocation and molecular mimicry are directly related to this condition ^[8]. Even though the microorganisms of gut microbiota do not directly induce tumorigenesis, they could interact with the immune system to indirectly promote the proliferation of cancer cells ^[9].

That is why, knowing that diet has a significant impact on the establishment and composition of gut microbiota throughout life ^[10], this review aims to provide information about the relationship between the consumption of probiotics and prebiotics and the establishment of balanced gut microbiota. Moreover, the generalities of the microbiota and its importance in the establishment and development of chronic and degenerative diseases are disclosed. The relationship between the gut microbiota–brain axis, its importance in the development of psychiatric and neurodegenerative diseases, as well as its association with the development of brain cancer, have also been addressed. Finally, the use of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) and their impact on the generation of beneficial populations in the digestive system, has also been mentioned in this review.

2. Human Gut Microbiota: Importance and Composition

The gut microbiota is a group of organisms that provides various benefits and imparts resistance to the colonization of new species, maintaining a symbiotic relationship with the host. However, an imbalance in this complex community could lead to recolonization by pathogenic microorganisms, causing inflammatory processes and the evolution of various

diseases [11]. This suggests that gut microbiota maintains the homeostasis of the human intestine [12]. It provides various effects such as protection against pathogens, carbohydrate digestion, regulation of fat storage, production of essential vitamins, and modulation of the immune response, representing an environmental factor of great importance in human homeostasis [13].

The gut microbiota has prominent participation in various metabolic functions through the fermentation of indigestible carbohydrates and the production of short-chain fatty acids (SCFAs), with beneficial systemic effects [14]. Among the SCFAs, acetate, propionate, and butyrate are the most frequently produced [15]. Acetate is the SCFA achieving the highest concentration in plasma, which has been related to low plasma insulin levels, propionate contributes to gluconeogenesis in the liver, and butyrate is used mainly as an energy source by the gut mucosa [16]. Additionally, gut microbiota allows the production of ketone bodies and carbon dioxide, as well as the regulation of energy homeostasis by stimulating intestinal enteroendocrine cells [16][17][18].

In addition to metabolic functions, gut microbiota contributes to the prevention of colonization of pathogenic microorganisms. Consequently, there is a competition for nutrients, which stimulates innate immunity through the secretion of IgA [19][20] and the activation of Toll-like cell receptors (TLCR). These compounds are capable of identifying molecular patterns associated with microorganisms that structurally include lipopolysaccharide of bacterial origin (LPS), lipoprotein, flagellin, and DNA of pathogens [14]. That is why the immunomodulatory activity exerted by the intestinal microbiota is involved in the interaction with cells of the immune system, participating in both the stimulation of innate immunity and the maturation and subsequent development of adaptive immunity [21][22].

This is carried out through bidirectional communication between the intestine and the brain through the enteric nervous system (ENS) [23]. Gut microbiota controls the ENS through the production, expression, and turnover of neurotransmitters and neurotrophic factors, the maintenance of the sensory barrier, the modulation of enteric sensory input, the production of bacterial metabolites, and the immune regulation of the mucosa [14][24]. Additionally, evidence indicates an association between mood disorders and dysbiosis [25]. This is due to the impact of neurotransmitters, such as serotonin and dopamine, originated by native gut microbiota, on brain alertness, mood control, memory, and the learning process of an individual [24][26].

Certainly, the success of the activities carried out by the intestinal microbiota depends to a great extent on its composition, which changes over time according to the different stages of an individual's life. This microbiota begins to appear from gestation and continues to develop in parallel with the host, fulfilling the necessary functions for the maintenance of homeostasis.

Approximately 106–1014 microorganisms belonging to the domains eukaryotic, archaea, and bacteria colonize the human gastrointestinal tract. Gut microbiota is composed of approximately 1000 species, and the main phyla are Firmicutes and Bacteroidota, and, to a lesser extent, Fusobacteria, Cyanobacteria, Proteobacteria, Verrumicrobia, and Actinobacteria can also be found [27]. However, this composition undergoes changes over time (Figure 1) and the dominant bacterial phyla are different at each stage of human life [2].

Intestinal colonization begins in the gestational stage. Some studies have been able to determine the presence of various microorganisms in the placenta, umbilical cord, and amniotic fluid, Proteobacteria and Actinobacteria being the most predominant at this stage [28][29][30]. Later, during natural childbirth, newborns are colonized by taxa that originate in the mother's vagina, while newborns delivered by cesarean section will be colonized by microorganisms present on the skin [31]. After birth, the intestine is progressively colonized by various microbial strains.

By the age of three, the microbiota has stabilized. However, bacterial strains will undergo significant fluctuations and changes over time, modifying their composition and gene expression. These modifications are due to anatomical, dietary, nutritional, and environmental alterations [6]. Additionally, the composition will also be determined by pathological disorders, such as gastrointestinal and systemic infections, as well as by the use of pharmacological agents, such as antibiotics, laxatives, prokinetics, and probiotics [32][33].

During older age, a restructuring in the intestinal microbiota has been observed. [34] reported significant changes in subjects older than 65 years, specifically an increase in the abundance of Bacteroidota and Proteobacteria. It has been hypothesized that alterations in the microbiota upon reaching an older age are mainly due to physiological changes in the gastrointestinal tract. Among these changes are the decrease in esophageal contractions and peristaltic movements, alteration in the gastric lining and fibrosis, the presence of low-grade chronic inflammation, and eating habits [35].

3. Role of Gut Microbiota in Human Health

Diseases such as obesity and DM2, and, in general, metabolic syndrome are related to dysbiosis [7][32][36]. One of them is the type of carbon source for obtaining energy. The second is related to the modulation of some human genes and proteins, which are involved in the regulation of energy expenditure. Finally, the third mechanism is associated with the regulation of the levels of LPS of bacterial origin into the plasma, which can induce chronic subclinical inflammation.

Most human studies indicate that an increase in the Firmicutes/Bacteroidota ratio is related to an increase in a low-grade inflammation state. Additionally, the little diversification of the intestinal microbiota is also associated with greater insulin resistance, inflammation, and adiposity [37][38]. This information is reinforced with metagenomic studies of the human intestinal microbiota relating not only obesity and insulin resistance, but also the increase of various markers, including TNF- α interleukin 6, and other proinflammatory cytokines [39][40][41].

Thus, the role of the intestinal microbiota in obesity and diabetes has also been demonstrated during the transplantation of fecal microbiota from lean human donors to obese human recipients [42]. Microbiota transplantation in these conditions increases insulin sensitivity and, therefore, there is better control of glycemic levels in subjects with metabolic syndrome [43]. Furthermore, a significant reduction in body weight in overweight and obese subjects is achieved through treatment with probiotics that could colonize the gastrointestinal tract, as demonstrated by Kadooka et al. [44] by supplying *Lactobacillus gasseri* as a supplement.

In the specific case of diabetes, some studies have indicated changes in the composition or function of the intestinal microbiota in patients with this condition. It is known that dysbiosis in this pathology is related to a decreased population of butyrate-producing bacteria, such as *Faecalibacterium prausnitzii* and *Roseburia intestinalis* [45]. The intestinal production of SCFAs, such as butyrate, is related to the beneficial effect on peripheral tissues, such as the liver, and adipose and connective tissue, also improving insulin sensitivity [46]. In addition, there is an increase in the populations of opportunistic pathogens, such as *Escherichia coli*, *Bacteroides caccae*, *Erysipelatoclostridium ramosum*, *Clostridium symbiosum*, and *Clostridium hathewayi*, which have also been related to dysbiosis [47].

Metagenomic studies have revealed a direct relationship between dysbiosis and diseases such as DM2 and obesity, since a decrease in the population of butyrate-producing species of the genera *Clostridium*, *Fecalibacteria*, and *Roseburia*, belonging to the phylum Firmicutes, has been demonstrated [32][39][48]. Furthermore, the Firmicutes/Bacterioidetes relationship is altered by the increase not only of *Escherichia coli*, but also of the phylum in general [32][49][50]. These results demonstrate a link between microbiota and metabolic diseases such as obesity and diabetes, and pose an area of opportunity for the development of new therapeutic strategies.

Despite the mutualistic relationship that exists between the microorganisms of the gut microbiota and the human, some bacteria can acquire virulence and change their symbiotic properties due to genetic, environmental, and dietary factors [51][52]. Various studies suggest that the alteration of gut microbiota, as well as its metabolic functions, are correlated with the appearance and progression of gastrointestinal diseases, such as severe diarrhea, celiac disease, and irritable bowel syndrome, among others [53][54][55].

Thus, the evolution of diseases such as intestinal inflammation is governed by complex interactions between several factors: environmental risks, host genetics, and the state of gut microbiota [56][57]. However, it is gut microbiota that has a direct effect when there is a reduction in the population of Firmicutes [51]. This fact is well documented through clinical studies that show that the diversity and richness of the microbiota are significantly reduced in patients with intestinal inflammation [51][53][58]. Furthermore, the pathogenesis of this disease is characterized by the accumulation of certain pathobionts, such as *Escherichia coli* and *Ruminococcus gnavus* [59][60].

On the other hand, in ulcerative colitis, which is characterized by inflammation and ulceration of the lining of the colon, an adaptation of microbial species such as *Bacteroides fragilis* and *Escherichia coli* has been observed. Similarly, the presence of pathogenic microorganisms adhered to the intestinal wall of patients with irritable bowel syndrome has been manifested [61][62][63]. Furthermore, there is an increase in the Firmicutes/Bacteroidota ratio compared to that of healthy patients [63][64]. Specifically, there is a greater number of species of the family Ruminococcaceae and *Clostridium* cluster XIVa and a smaller number of *Bacteroides* [65].

In certain gastrointestinal diseases, dysbiosis has been related to genetic mutations [66]. For example, in the case of celiac disease, it has been reported that mutations present in genes involved in the secretion of intestinal mucus, the structure of associated bacteria, and a reduction in bacterial diversity and richness, influence the pathogenesis of the disease [67]. This

disease presents a series of symptoms of chronic immune-mediated inflammation in the small intestine due to a lower abundance of *Bifidobacterium* spp. This marks an association with an increased risk for the development of autoimmune diseases [52].

More in-depth studies are required to explore the therapeutic potential of the modulation of gut microbiota in the treatment of gastrointestinal diseases since, due to scientific evidence, the phenotype of commensal bacteria can go from symbiotic to pathogenic in response to various risk factors [51]. These phenotypic alterations modify not only the host's immune system, but also impact the structure and diversity of gut microbiota, which leads to the development and/or progression of a greater diversity of gastrointestinal diseases [68][69][70].

The microbiota–intestine–brain axis (Figure 2) is a bidirectional communication network that includes the central nervous (CNS), autonomic nervous (ANS), and enteric nervous (ENS) systems. The immune system, the endocrine system, and the intestinal microbiota also belong to this axis [71]. Given the complexity of this network, possible intervention strategies have been explored, aimed at the dysbiosis of gut microbiota present in various neurological and psychiatric disorders, including the use of probiotic, prebiotic, and symbiotic foods [2].

Furthermore, various studies indicate that the intestinal microbiota influences the gut–brain system, triggering the symptoms that occur during a state of anxiety and stress [72]. This system regulates the effects of various metabolites, such as neurotransmitters, hormones, and SCFA, that are produced by gut microbiota and impact on CNS functions [73]; (3) Regulation of signals and the synthesis of neurotransmitters. Gut microbiota apparently modulates the expression of central neurotransmitters and related receptors, and some species produce neurotransmitters, such as acetylcholine, dopamine, and adrenaline, or induce their synthesis [74][75][76]; (4) Production of SCFA. Gut microbiota is capable of modulating the maturation of the microglia and the permeability of the blood–brain barrier through the synthesis of SCFA [75][77][78]; (5) Immunomodulation.

Involvement of the vagus nerve. There is a connection between the ENS and the CNS that provides a direct communication pathway between gut microbiota and the CNS [79][80];

Participation of the circulatory system. This system regulates the effects of various metabolites, such as neurotransmitters, hormones, and SCFA, that are produced by gut microbiota and impact on CNS functions [73];

Regulation of signals and the synthesis of neurotransmitters. Gut microbiota apparently modulates the expression of central neurotransmitters and related receptors, and some species produce neurotransmitters, such as acetylcholine, dopamine, and adrenaline, or induce their synthesis [74][75][76];

Production of SCFA. Gut microbiota is capable of modulating the maturation of the microglia and the permeability of the blood–brain barrier through the synthesis of SCFA [75][77][78];

Immunomodulation. Gut microbiota influences the activation of peripheral immune cells that regulate CNS immune reactions [81][82].

Studies have shown differences between patients with neurological disorders and healthy controls [83]. In healthy individuals, an analysis of 16s rRNA from fecal microbiota showed that bacteria corresponding to the phyla Firmicutes and Bacteroidota have a higher proportion than that of the phyla Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia [84]. Additionally, microbial abundance and diversity are significantly reduced in patients with depression and anxiety disorders [83]. This dysbiosis causes both microorganisms and the products of their metabolism to induce inflammation at the brain level through blood circulation and induce the production of various cytokines, such as IL-6, IL-1 β , and TNF- α [83], which, in turn, modulate various brain processes that affect mood and behavior [85].

In the case of Parkinson's patients, gut microbiota alterations coincide with an aggravation of the condition [86][87][88][89], which is related to a lower concentration of Prevotellaceae species compared to the relative abundance of Enterobacteriaceae in the feces of these patients [90]. Likewise, a decrease in the Prevotellaceae population generates an increase in intestinal permeability and systemic exposure to LPS [80][91]. This endotoxin induces systemic inflammation by the production of proinflammatory cytokines that interact with TLR and nuclear factor-kappa B (NF- κ B). Once LPS breaks the blood–brain barrier [92][93].

Another condition related to dysbiosis is Alzheimer's, a neurodegenerative disorder that leads to cognitive dysfunction [94]. An increase in intestinal permeability, as a consequence of dysbiosis, has, in turn, been associated with an increase in the concentration of various microorganisms, as well as products derived from their metabolism [95][96][97]. In general, it has

been observed that gut microbiota in people with this condition is represented by an increase in Proteobacteria and a decrease in SCFA-producing bacteria [98]. Thus, the use of probiotics has been explored as an alternative to improve the cognitive functions of patients and the decrease in cytokines that lead to neuroinflammation [99][100][101].

It has been highlighted that pathogenesis is not only attributed to genetic susceptibilities, but also to mechanisms that include abnormal microbial translocation, molecular mimicry, and dysregulation of local and systemic immunity [8]. In this context, it has been reported that some microorganisms belonging to gut microbiota have oncogenic effects or oncolytic activity in tumor cells. Approximately 20% of cancers are attributable to infectious agents, including bacteria [102]. In addition to this, it has been observed that there is a difference between healthy individuals and cancer patients in terms of population and microbial diversity present at the intestinal level [103].

The link between gut microbiota and carcinogenesis has been described, with an emphasis on bacterial metabolites. Thus, the main mechanisms of bacterial-mediated carcinogenesis are mainly based on the effects of the specific toxins or virulence factors produced [104][105]. Furthermore, microbial metabolites, such as polyamines and secondary bile acids, are also involved in cancer cell proliferation and tumor induction through the β -catenin signaling pathway [106], epidermal growth factor receptor (EGFR) transactivation [107], and increased COX-2 activity [108].

Due to this interaction, there is an effect on the inhibition of bacterial adhesion and colonization, as well as the induction of cell differentiation [109]. In this sense, microbial species such as *Bacteroides fragilis* induce the differentiation of T cells CD4+ to regulatory T cells (Treg cells) [110], which are capable of secreting large amounts of anti-inflammatory cytokines, such as IL-10, and recognizing antigenic substances associated with the bacterial genera *Clostridium* and *Bacteroides* [111][112]. Metabolites produced by microorganisms enter the bloodstream and, therefore, affect the immune response in distant organs through interaction with TLR [109].

Although the microorganisms of gut microbiota do not directly induce tumorigenesis, they could interact with the immune system to indirectly promote the proliferation of cancer cells [9]. Thus, a defective immune response increases the abundance of certain bacterial genera and triggers signaling pathways that lead to the transcription of oncogenes [9][113]. In addition to this, gut microbiota can indirectly promote cancer by inducing inflammation or immunosuppression through the production of cytokines [114][115]. Finally, the development of various malignant neoplasms, including some types of cancer (gastric, colorectal, pancreatic, breast, and brain cancer), is currently associated with variations in gut microbiota composition [116].

Moreover, a lower probability of survival in patients with colon cancer has been associated with *F. nucleatum* abundance [117] due to the induction of chemoresistance, which activates autophagy [115], leading to treatment failure or disease recurrence [113]. The species mentioned above induce tumor proliferation [118], promote inflammation [119], protect the tumor from the mechanisms exerted by the immune system [120], and cause damage to host cell DNA [121]. As in other types of cancer, in colorectal cancer, special emphasis has been placed on protein toxins produced by the intestinal microbiota [122]. The procarcinogenic effect of these toxins could be due to the direct attack on DNA, which leads to genomic instability or proliferation and induction of resistance to apoptosis in cancer derived from cellular signaling alterations [123].

This condition represents one of the most serious malignant neoplasms, with overall survival lower than 5 years [8]. Because surgical resection is often not possible, treatment is focused on chemotherapy. However, some patients could develop chemoresistance [124] associated with gut microbiota, which has a major impact on pancreatitis and pancreatic ductal adenocarcinoma [124][125].

In the same way that *Fusobacterium nucleatum* has been associated with colorectal cancer, it is currently known that this microorganism induces chemoresistance, autophagy, and inflammation in pancreatic carcinogenesis processes [115][126]. Additionally, in patients with this condition, an increase in Proteobacteria and Verrucomicrobia, and a decrease in Firmicutes and Bacteroidota have been observed, which are accompanied by the activation of inflammatory pathways in tumor tissues [127].

Furthermore, it has been observed that the presence of intratumoral pathogens and bacteria, such as *Acinetobacter*, *Aquabacterium*, *Oceanobacillus*, and *Rahnella*, are associated with a higher risk of presenting pancreatic ductal adenocarcinoma [128][129]. The development of this disease involves the intestinal mucosa, epithelial and dendritic cells (DC), and different cells from the immune system [130]. The above-mentioned microorganisms are part of the gut microbiota and promote the development of adenocarcinoma through the release of a large number of metabolites [114] which interact with TLR and also induce systemic inflammation and immune responses associated with pancreatic carcinogenesis and therapeutic resistance [131].

The most common type of cancer affecting women worldwide is breast cancer. More than 40,000 deaths per year occur, even though there has been significant progress in its diagnosis and treatment ^[132]. A strong link between dysbiosis and the appearance of neoplasms, including those of breast cancer, has been shown ^[105]. Thus, recent research has focused on the influence of gut microbiota on the development of breast cancer, beyond genetic, environmental, and lifestyle factors ^[133].

The differences in the concentration of *Bifidobacterium*, *Faecalibacterium prausnitzii*, and *Blautia* have been used as biomarkers associated with the clinical stage of breast tumors ^[134]. In addition, these differences are also associated with the body mass index of the patients. Indeed, it has been observed that overweight and obese women with breast tumors present lower concentrations of Firmicutes, *Faecalibacterium prausnitzii*, and *Blautia* spp., as well as *Akkermansia muciniphila* prevalence, compared to patients with normal weight ^{[134][135]}.

Likewise, in postmenopausal women with breast cancer, there is an alteration in the composition of the fecal microbiota, as well as a lower microbial diversity ^[136]. Specifically, elevated levels of Clostridiaceae, *Faecalibacterium*, and Ruminococcaceae, as well as a decrease in the proportion of *Dorea* and Lachnospiraceae, have been reported ^[137]. Similarly, an increase in the population of species such as *Escherichia coli*, *Citrobacter koseri*, *Acinetobacter radioresistens*, *Salmonella enterica*, and *Fusobacterium nucleatum*, among others, has been observed ^[138]. However, some factors must be taken into account when determining the characteristics of the gut microbiota of patients with breast cancer, such as age, ethnicity, and geographic location ^[136].

Gastric cancer is one of the most common neoplasms, which is characterized by acute and persistent inflammation ^[139]. In the same way, as in other types of cancer, the gut microbiota is related to the development of this disease and *Helicobacter pylori* is the main carcinogenic agent ^[140]. The mechanism of action of *H. pylori* to produce inflammation is associated with the degree of specific virulence of each strain ^[141]. Similarly, the TLR and NOD-like receptors that recognize the presence of *H. pylori* are also associated with the chronic carcinogenesis process ^[142].

First, immune cell infiltration, including neutrophils and macrophages, increases, leading to the production of reactive oxygen and nitrogen species (RONS) ^[143]. RONS cause damage in the DNA leading to single-strand breaks and increased expression of oncogenes ^[144]. Alternatively, the transcription factor NF- κ B is activated by RONS, inducing the expression of oncogenes and cell cycle regulators ^[145]. In addition, this factor translocates to the nucleus, forming an XPC protein complex (XPG and XPF) which cleaves the promoter regions of genes, impacting gene expression because of double-strand breaks ^[146].

Although gastric acidity serves as an important barrier that limits the entry of microbes into the gastrointestinal tract ^[139], *H. pylori* can survive the conditions present in the stomach, but its ability to colonize gastric glands is restricted due to the large amount of acid produced in these cavities ^[147]. However, concomitant inflammation and the presence of *H. pylori* increases damage in various regions of the stomach. The result of this damage is atrophy associated with the abundance of this microorganism, which is greater in gastric cancer than in gastritis and intestinal metaplasia ^{[148][149]}.

Additionally, in subjects with *H. pylori* infection and precancerous gastric lesions, variations in the relative abundance of the dominant phyla, such as Bacteroidota, Firmicutes, and Proteobacteria, have been observed in fecal microbiota ^[150]. Other specific bacteria related to gastric carcinogenesis, such as *Peptostreptococcus stomatis*, *Slackia exigua*, *Parvimonas micra*, *Streptococcus anginosus*, and *Dialister pneumosintes*, have been studied, but *H. pylori* is the microorganism commonly associated with gastric cancer ^[151].

Gut microbiota and brain cancer association is a new topic that has gained interest in recent years ^[152]. This relationship can be explained by the mechanisms present in the microbiota–gut–brain axis, since it has been reported that they could influence the development or suppression of brain tumors ^[82].

Tryptophan is a substrate used by intestinal microorganisms to produce indoles. This amino acid is metabolized in the kynurenine pathway, resulting in the biosynthesis of nicotinamide adenine dinucleotide and various neuroactive intermediates ^[152]. In this context, it has been reported that a dysregulation of the kynurenine pathway could contribute to the development of brain cancer by interrupting the antitumor immune response ^{[153][154]}. Likewise, gut microbiota could influence the brain tumor microenvironment through different mechanisms: (1) control of the expansion and activation of T cells ^[155]; (2) microglia ^{[156][157][158]}; (3) cytokine and arginine production, and tryptophan availability via kynurenine ^[157] ^[159]; and (4) production of reactive oxygen species (ROS) and generation of antioxidants ^{[160][158]}.

4. Modulation of Gut Microbiota through Diet

Diet is a preponderant factor that affects the establishment and composition of the gut microbiota throughout life ^[160], and changes during adulthood could affect intestinal homeostasis ^[161]. When there is a reduced dietary diversity and a lack of essential nutrients, a dysbiosis of gut microbiota occurs, leading to the appearance of various disorders ^[162]. The species that comprise the human gut microbiota require a wide range of nutrients and energy sources to promote growth, and they have a direct relationship with the effects associated with human health ^[161].

It has been highlighted that the intake of specific nutritional elements (carbon sources, nitrogen sources, growth factors, etc.) contributes to the diversification in the composition of the intestinal microbiota ^[163]. In this way, auxotrophies of some microorganisms that maintain the balance of the intestinal microbiota have been determined ^{[164][165]}. ^[166] point out that *Bifidobacterium infantis* and *Bacteroides thetaiotaomicron*, which are present in the gut microbiota of infants and adults, require oligosaccharides present in milk and the mucosa of the large intestine. This suggests that the particular carbon metabolism of each of the phyla plays a preponderant role in both the survival and long-term stability of gut microbiota.

The amount, type, and balance of proteins, carbohydrates, and fats of the diet greatly impact the gut microbiota ^[167], mainly due to the products from their degradation. This degradation causes the formation and release of SCFAs, phenols, indoles, and amines, with a wide range of physiological effects on the host ^[168].

It has been reported that a diet rich in prebiotics, such as inulin, oligofructose, and fructooligosaccharides, among other polysaccharides of plant origin, increase the growth of lactobacilli and bifidobacteria in gut microbiota ^[169]. Contrarily, the intake of a diet rich in simple carbohydrates and high in fat affects the abundance of Firmicutes phylum populations and decreases Bacteroidota, which, in some studies, has been related to obesity ^{[170][171]}.

The consumption of protein and fat of animal origin have also been linked to Bacteroidota phylum, while carbohydrates have been related to Bacteroidetes, as well as Firmicutes phylum, indicating an association with dietary patterns ^[172]. Additionally, the type of diet has an influence on intestinal transit time, which is faster with a plant-based diet than with an animal-based one ^{[172][173]}. Plant-based diets are a source of nondigestible fiber. It is generally accepted that the benefits of fiber intake on health are derived from laxation, increasing fecal bulking, and stool water content that stimulate mucus secretion and peristalsis ^[174].

Sprong et al. ^[175], in an in vivo study, observed a significant increase in the counts of bifidobacteria and lactobacilli when the diet included whey cheese or casein supplemented with threonine or cysteine. According to the aforementioned studies, gut microbiota composition can be positively modified through diet. Despite this, current food habits are characterized by no significant consumption of fruits, vegetables, and fish, leading to several health disorders, such as diabetes, hypertension, cardiovascular accidents, increased levels of cholesterol and triglycerides, greater insulin resistance, and inflammation, among others ^[176].

That is why there is an urgent need to develop efficient strategies aimed at reversing, preventing, and treating metabolic disorders associated with the dysbiosis process ^[177]. It can be achieved from a pharmacological and nutritional approach by incorporating prebiotics, probiotics, symbiotics, and other supplements into the diet. With their consumption, gut microbiota balance could be re-established or a healthy gut microbiota could be maintained when homeostasis has been lost due to an adverse condition ^[178].

The use of probiotic species has been relevant in the treatment of human and animal diseases due to their effect on the modulation of the intestinal microbiota. The potential that probiotic microorganisms represent has driven research for the production of probiotic foods and the modulation of gut microbiota, promoting their consumption ^[179].

The Food and Agriculture Organization and the World Health Organization define probiotics as strains of live microorganisms that confer beneficial effects on health when administered in specific amounts. In recent years, a new terminology that provides a comprehensive approach to all the beneficial aspects of probiotics has been suggested. In this way, three main classes of probiotics have been proposed, including: (1) true probiotic (TP), to refer to a viable and active probiotic cell; (2) pseudo-probiotic (PP), which refers to a viable and inactive cell as a spore or vegetative body; and, (3) phantom probiotic (GP), to refer to a dead/nonviable cell that is intact or lysed ^[180]. According to this new terminology, a probiotic could be defined as a viable or nonviable microbial cell in a vegetative or spore state, intact or lysed, that is potentially healthy for the host ^[181].

Since the beginning of the 20th century, when the importance of the consumption of probiotic foods with a specific mixture of microorganisms began to be highlighted ^[178], studies on this type of food have been intensified in animal and human models. In this way, the beneficial effect of several species of specific strains, which have immunological, metabolic, and neuroendocrine activity, has been verified ^[178]. Certainly, the beneficial effects exerted by probiotic microorganisms are

numerous, highlighting their effect on the development of microbiota that inhabits the organism (Table 1). Thus, it has been determined that the consumption of probiotic microorganisms helps to regulate intestinal homeostasis, maintaining an adequate balance between pathogens and bacteria necessary for the correct functioning of the organism [182].

Various genetic and molecular studies have made it possible to determine that probiotics exert beneficial effects through four main mechanisms (Figure 4): (1) the immunomodulation they exert in the host; (2) antagonism through the production of antimicrobial substances; (3) the inhibition of bacterial toxins; and (4) competition with pathogens by adhesion to the epithelium and by nutrients [183][184]. These mechanisms are relevant in the prophylaxis, treatment of infections, and maintenance of the host's intestinal microbiota [181].

It is in the maintenance of the microbiota that probiotics play an important role in processes such as the absorption of cholesterol, the regulation of blood pressure, and glucose metabolism. In vivo studies have shown that the administration of *Bifidobacterium* and *Lactobacillus* strains has a significant impact on the composition of gut microbiota [185][186][187]. [188] supplemented a diet with the probiotic strains *Lactilactobacillus cruvatus* HY7601 and *Lactiplantibacillus plantarum* KY1032, observing a decrease in the concentration of proinflammatory genes, greater expression of genes related to the oxidation of fatty acids in the liver, thus, as relevant alterations in the diversity and function of the microbiota. However, in clinical studies, this evidence is not conclusive, which is why it has been suggested that the observed changes may only occur in microbial metabolism at the level of SCFAs production and not in the microbial population [189].

Contrarily to these observations, several studies have demonstrated that probiotics produce changes in specific bacterial communities. Similarly, it has been observed that the administration of *Lactobacillus salivarius* Ls-33 modifies the populations of fecal bacteria in adolescents with obesity, including several groups of clostridia [190]. On the other hand, in patients with irritable bowel syndrome, considerable fluctuations in clostridium populations have been observed. *Lactis*, which is also related to the decrease in the concentration of pathogenic bacteria and the modification of the colonic production of SCFAs [191][192].

Probiotics play important roles when they come into contact with the rest of the microbial communities, influencing the metabolism of other members of the host's microbiota [189]. An example of this is the bifidobacteria that metabolize a great diversity of carbohydrates, which come from the diet or the intestinal mucosa of the host and produce acetic and lactic acid in different proportions [193]. Specifically, *Bifidobacterium bifidum* increases its metabolism when it grows along with other species, such as *Bifidobacterium breve*, which enhances the catabolism of glycosylated compounds, such as mucin and 3-sialyllactose [194][195].

Nevertheless, a modification of the intestinal microbiota through the consumption of probiotics is not the only way to produce a beneficial effect in the host. The probiotic effect can be manifested through the interaction with the immune system [196], but it is necessary to highlight the challenges and opportunities regarding the studies of probiotic microorganisms capable of generating long-term effects after modifying the intestinal microbiota. In this context, in addition to traditional health-promoting bacteria (*Bifidobacterium* and lactic acid bacteria), in recent years, the beneficial effect has been noted after the therapeutic use of next-generation probiotics [197]. This concept includes microorganisms such as *Akkermansia muciniphila* whose effect is associated with glucose metabolism, lipid metabolism, and intestinal immunity [198], for which it has been proposed as a target for immunotherapy in various types of cancer [197][199].

[200] determined beneficial changes in the gut microbiota of healthy adults after the consumption of *Lactobacillus casei* Zhang. The effect was related to enterotypic changes due to the increment in concentration of beneficial microorganisms, inhibiting the growth of pathogenic ones. The consumption of probiotic fermented milk also has proved to generate beneficial changes in obese patients [201]. The main effect is related to a decrease in *Collinsella*, a proinflammatory biomarker, and an increase in *Akkermansia* concentration, as well as an improvement in oxidative stress biomarkers [202].

Pharmacological treatments should not be replaced by probiotics, but their consumption could be incorporated into the diet during disease management to provide their well-documented beneficial effects. Thus, the development of probiotic foods containing vehicles for microorganisms that exert a benefit in the modulation of gut microbiota is an area of opportunity in the food science and technology field [203]. Of course, one of the most important challenges is to guarantee the survival of probiotic microorganisms in sufficient concentrations to reach the adequate amounts that promote changes in metabolic functions of gut microbiota.

Prebiotics are currently defined by ISAPP as "a substrate that is selectively utilized by host microorganisms conferring a health benefit" [204]. Among the best-known prebiotics are inulin, fructooligosaccharides, galactooligosaccharides, and lactulose [205]. These molecules are selectively fermented in the colon, conferring beneficial effects to the host, including stimulation of both growth and metabolic activity of various bacterial groups of the intestinal microbiota [206], mainly probiotics, which use prebiotics as a carbon source [204][207].

Recently, another type of compound including polyphenols has been proposed as a prebiotic since they meet the current definition previously mentioned. It appears that their beneficial effect on the host depends on the microbial utilization and the metabolites produced rather than on parent compounds. However, as studies on these emerging prebiotics are not yet conclusive, more evidence on the health benefits associated with polyphenols and probiotic interaction is needed [207].

Bacterial fermentation of prebiotics leads to the production of SCFAs, mainly butyrate, acetate, and propionate [208]. These acids have an impact on various cellular mechanisms, such as the activation of G-protein-coupled receptors and the inhibition of histone deacetylation [209]. Likewise, they act as a source of energy for colorectal tissues, exert an anti-inflammatory effect, and act as molecules that are related to the signaling pathways of the microbiota–intestine–brain axis [210]. In addition, other organic acids, such as formate, lactate, and succinate, decrease intestinal pH, preventing the growth of pathogenic bacteria [211].

Thus, it has been indicated that the consumption of prebiotics by healthy adults increases the concentration of *Bifidobacterium* spp. in gut microbiota [212]. However, the composition of the microbiota after the consumption of certain prebiotics is not limited only to these taxa. Through the application of sequencing techniques and metagenomic analysis, it has been shown that prebiotics affect the entire composition of gut microbiota (Table 2) [213][214][215].

On the other hand, studies also suggest that beneficial changes in gut microbiota are maintained with continuous consumption of prebiotics. In addition, microbial diversification is dependent on the basal or indigenous microbiota, including the growth of specific species and the enzymatic capacity of some strains [210][216]. For example, resistant starch is considered a prebiotic, since it can be fermented in the colon, conferring beneficial metabolic effects. Among the most studied benefits, the following stand out: an increase in the turnover of bile salts, laxative effect, control of blood lipid levels, and a decrease in the postprandial glucose response [217].

The metabolic effects, as well as the group of bacteria that are favored after the incorporation of starch, depending on the type of resistant starch that is consumed [218]. For example, type 4 resistant starches have been found to favor the growth of *Bacteroides* and *Parabacteroides* spp. in humans [219], and *Bifidobacterium*, *Akkermansia*, and genera of *Allobaculum* in murine models [220]. Regarding type 3 resistant starches, several studies using animal and human models have shown that they favor the growth of beneficial bacterial populations, mainly SCFA-producing genera, such as *Prevotella*, *Ruminococcus*, *Lachnospiraceae*, *Veillonellaceae*, *Bulleidia*, and *Dialister* [221].

Alginate is another polysaccharide that has stood out for its prebiotic properties. Its consumption modifies the intestinal microbiota by increasing the relative abundance of microbial populations such as *Roseburia*, *Ruminococcus*, and *Lachnospira*, which are SCFA producers. Additionally, an increase in the concentration of bifidobacteria due to the consumption of alginate has been reported [221].

In the same way, an increase in the concentration of *Prevotella* and *Roseburia* has been observed by the in vitro fermentation of prebiotics such as inulin, galacto-oligosaccharides (GOS), and xylo-oligosaccharides (XOS) of corn and sugar cane with a high content of fiber and oat β -glucans. Furthermore, there is a concomitant increase in propionate production. Similarly, inulin, XOS, and GOS have a strong bifidogenic effect on the microbial composition and are precursors of the formation of butyrate by native microorganisms of the intestinal microbiota [222].

Other studies highlight the effects of barley β -glucans, which, when administered in low doses, significantly increase the count of bifidobacteria and lactobacilli in healthy subjects. Similarly, β -glucans from wheat flour and whole barley pasta increase the levels of *Roseburia hominis*, *Clostridium orbiscindens*, *Clostridium* sp., and *Ruminococcus* sp. in the gut microbiota. At the same time, a reduction in the levels of Firmicutes and Fusobacteria is observed, and it has been verified that the consumption of β -glucans affects the increase in the concentration of acids such as 2-methylpropanoic, acetic, butyric, and propionic [220].

In addition to prebiotic sources of plant origin, the effect of bovine milk oligosaccharides has also been evaluated, which, in combination with GOS, decrease the concentration of *Clostridium perfringens*, with a simultaneous increase in *Bifidobacteria*, lactate, and acetate [223]. Despite the results, some authors suggest that prebiotic supplementation does not always lead to a global change in the alpha or beta diversity of gut microbiota. However, a modification is observed in the abundance of certain bacterial taxa, such as *Ruminococcaceae* (*Clostridium* cluster IV), *Parabacteroides*, and *Phascolarctobacterium* [224].

Currently, the role of FODMAPs in the intestinal microbiota has been studied, noting that the low intake of these compounds is related to a reduction in the symptoms of various gastrointestinal diseases, including irritable bowel syndrome and inflammatory bowel disease [225][226]. Conversely, a diet high in FODMAPs seems to have an opposite

effect to prebiotic supplementation, decreasing *Bifidobacterium* populations and increasing bacteria associated with dysbiosis [225]. However, more studies are needed to evaluate the effects of a diet high in FODMAPs on the composition of gut microbiota, focusing on the persistence of changes in microbial composition and adverse health effects.

References

1. Breban, M. Gut microbiota and inflammatory joint diseases. *Jt. Bone Spine* 2016, 83, 645–649.
2. Wu, W.; Kong, Q.; Tian, P.; Zhai, Q.; Wang, G.; Liu, X.; Zhao, J.; Zhang, H.; Lee, Y.K.; Chen, W. Targeting Gut Microbiota Dysbiosis: Potential Intervention Strategies for Neurological Disorders. *Engineering* 2020, 6, 415–423.
3. Thakur, B.K.; Saha, P.; Banik, G.; Saha, D.R.; Grover, S.; Batish, V.K.; Das, S. Live and heat-killed probiotic *Lactobacillus casei* Lbs2 protects from experimental colitis through Toll-like receptor 2-dependent induction of T-regulatory response. *Int. Immunopharmacol.* 2016, 36, 39–50.
4. Ussar, S.; Griffin, N.W.; Bezy, O.; Fujisaka, S.; Vienberg, S.; Softic, S.; Deng, L.; Bry, L.; Gordon, J.I.; Kahn, C.R. Interactions between Gut Microbiota, Host Genetics and Diet Modulate the Predisposition to Obesity and Metabolic Syndrome. *Cell Metab.* 2015, 22, 516–530.
5. Margolis, K.G.; Cryan, J.F.; Mayer, E.A. The Microbiota-Gut-Brain Axis: From Motility to Mood. *Gastroenterology* 2021, 160, 1486–1501.
6. Derrien, M.; Alvarez, A.-S.; de Vos, W.M. The Gut Microbiota in the First Decade of Life. *Trends Microbiol.* 2019, 27, 997–1010.
7. Relman, D.A. The Human Microbiome and the Future Practice of Medicine. *JAMA* 2015, 314, 1127–1128.
8. Zhang, X.; Chen, B.-D.; Zhao, L.-D.; Li, H. The Gut Microbiota: Emerging Evidence in Autoimmune Diseases. *Trends Mol. Med.* 2020, 26, 862–873.
9. Gagliani, N.; Hu, B.; Huber, S.; Elinav, E.; Flavell, R.A. The Fire Within: Microbes Inflammation Tumors. *Cell* 2014, 157, 776–783.
10. Lankelma, J.M.; Nieuwdorp, M.; De Vos, W.M.; Wiersinga, W.J. The gut microbiota in internal medicine: Implications for health and disease. *Neth. J. Med.* 2015, 73, 61–68.
11. Gibson, M.K.; Pesesky, M.W.; Dantas, G. The Yin and Yang of Bacterial Resilience in the Human Gut Microbiota. *J. Mol. Biol.* 2014, 426, 3866–3876.
12. Clemente, J.C.; Ursell, L.K.; Parfrey, L.W.; Knight, R. The Impact of the Gut Microbiota on Human Health: An Integrative View. *Cell* 2012, 148, 1258–1270.
13. Martínez, I.; Müller, C.E.; Walter, J. Long-Term Temporal Analysis of the Human Fecal Microbiota Revealed a Stable Core of Dominant Bacterial Species. *PLoS ONE* 2013, 8, e69621.
14. Adak, A.; Khan, M.R. An insight into gut microbiota and its functionalities. *Cell. Mol. Life Sci.* 2018, 76, 473–493.
15. Duncan, S.H.; Belenguer, A.; Holtrop, G.; Johnstone, A.M.; Flint, H.J.; Lobley, G.E. Reduced Dietary Intake of Carbohydrates by Obese Subjects Results in Decreased Concentrations of Butyrate and Butyrate-Producing Bacteria in Feces. *Appl. Environ. Microbiol.* 2006, 73, 1073–1078.
16. Morrison, D.J.; Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. *Gut Microbes* 2016, 7, 189–200.
17. Nicholson, J.K.; Holmes, E.; Kinross, J.; Burcelin, R.; Gibson, G.; Jia, W.; Pettersson, S. Host-Gut Microbiota Metabolic Interactions. *Science* 2012, 336, 1262–1267.
18. Rooks, M.G.; Garrett, W.S. Gut microbiota, metabolites and host immunity. *Nat. Rev. Immunol.* 2016, 16, 341–352.
19. Kau, A.L.; Planer, J.D.; Liu, J.; Rao, S.; Yatsunenko, T.; Trehan, I.; Manary, M.J.; Liu, T.-C.; Stappenbeck, T.S.; Maleta, K.M.; et al. Functional characterization of IgA-targeted bacterial taxa from undernourished Malawian children that produce diet-dependent enteropathy. *Sci. Transl. Med.* 2015, 7, 276ra24.
20. Wu, W.; Sun, M.; Chen, F.; Cao, A.T.; Liu, H.; Zhao, Y.; Huang, X.; Xiao, Y.; Yao, S.; Zhao, Q.; et al. Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43. *Mucosal Immunol.* 2017, 10, 946–956.
21. Perez-Cano, F.J.; González-Castro, A.; Castellote, C.; Franch, À.; Castell, M. Influence of breast milk polyamines on suckling rat immune system maturation. *Dev. Comp. Immunol.* 2010, 34, 210–218.
22. Odenwald, M.A.; Turner, J.R. The intestinal epithelial barrier: A therapeutic target? *Nat. Rev. Gastroenterol. Hepatol.* 2017, 14, 9–21.

23. Carabotti, M.; Scirocco, A.; Maselli, M.A.; Severi, C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. *Ann. Gastroenterol.* 2015, 28, 203–209.
24. Sarkar, A.; Lehto, S.M.; Harty, S.; Dinan, T.G.; Cryan, J.F.; Burnet, P.W. Psychobiotics and the Manipulation of Bacteria–Gut–Brain Signals. *Trends Neurosci.* 2016, 39, 763–781.
25. Zheng, P.; Zeng, B.; Zhou, C.; Liu, M.; Fang, Z.; Xu, X.; Zeng, L.; Chen, J.; Fan, S.; Du, X.; et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. *Mol. Psychiatry* 2016, 21, 786–796.
26. Harach, T.; Marungruang, N.; Duthilleul, N.; Cheatham, V.; Mc Coy, K.D.; Frisoni, G.; Neher, J.J.; Fåk, F.; Jucker, M.; Lasser, T.; et al. Reduction of Abeta amyloid pathology in APPS1 transgenic mice in the absence of gut microbiota. *Sci. Rep.* 2017, 7, 41802.
27. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K.S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.; Yamada, T.; et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010, 464, 59–65.
28. Jiménez, E.; Fernández, L.; Marín, M.L.; Martín, R.; Odriozola, J.M.; Nueno-Palop, C.; Narbad, A.; Olivares, M.; Xaus, J.; Rodríguez, J.M. Isolation of Commensal Bacteria from Umbilical Cord Blood of Healthy Neonates Born by Cesarean Section. *Curr. Microbiol.* 2005, 51, 270–274.
29. Moles, L.; Gómez, M.; Heilig, H.; Bustos, G.; Fuentes, S.; De Vos, W.; Fernández, L.; Rodríguez, J.M.; Jiménez, E. Bacterial Diversity in Meconium of Preterm Neonates and Evolution of Their Fecal Microbiota during the First Month of Life. *PLoS ONE* 2013, 8, e66986.
30. Perez-Muñoz, M.E.; Arrieta, M.-C.; Ramer-Tait, A.E.; Walter, J. A critical assessment of the “sterile womb” and “in utero colonization” hypotheses: Implications for research on the pioneer infant microbiome. *Microbiome* 2017, 5, 48.
31. Dominguez-Bello, M.G.; Costello, E.K.; Contreras, M.; Magris, M.; Hidalgo, G.; Fierer, N.; Knight, R. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc. Natl. Acad. Sci. USA* 2010, 107, 11971–11975.
32. Qin, J.; Li, Y.; Cai, Z.; Li, S.; Zhu, J.; Zhang, F.; Liang, S.; Zhang, W.; Guan, Y.; Shen, D.; et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature* 2012, 490, 55–60.
33. Scarpellini, E.; Ianaro, G.; Attili, F.; Bassanelli, C.; De Santis, A.; Gasbarrini, A. The human gut microbiota and virome: Potential therapeutic implications. *Dig. Liver Dis.* 2015, 47, 1007–1012.
34. Claesson, M.J.; Cusack, S.; O'Sullivan, O.; Greene-Diniz, R.; De Weerd, H.; Flannery, E.; Marchesi, J.R.; Falush, D.; Dinan, T.G.; Fitzgerald, G.F.; et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc. Natl. Acad. Sci. USA* 2011, 108, 4586–4591.
35. Franceschi, C. Inflammaging as a Major Characteristic of Old People: Can It Be Prevented or Cured? *Nutr. Rev.* 2008, 65, S173–S176.
36. Larsen, N.; Vogensen, F.K.; Van Den Berg, F.W.; Nielsen, D.S.; Andreassen, A.S.; Pedersen, B.K.; Al-Soud, W.A.; Sørensen, S.J.; Hansen, L.H.; Jakobsen, M. Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults. *PLoS ONE* 2010, 5, e9085.
37. Cornejo-Pareja, I.; Muñoz-Garach, A.; Clemente-Postigo, M.; Tinahones, F.J. Importance of gut microbiota in obesity. *Eur. J. Clin. Nutr.* 2018, 72, 26–37.
38. Pascale, A.; Marchesi, N.; Govoni, S.; Coppola, A.; Gazzaruso, C. The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: New insights into old diseases. *Curr. Opin. Pharmacol.* 2019, 49, 1–5.
39. Le Chatelier, E.; Nielsen, T.; Qin, J.; Prifti, E.; Hildebrand, F.; Falony, G.; Almeida, M.; Arumugam, M.; Batto, J.-M.; Kennedy, S.; et al. Richness of human gut microbiome correlates with metabolic markers. *Nature* 2013, 500, 541–546.
40. Kovatcheva-Datchary, P.; Nilsson, A.; Akrami, R.; Lee, Y.S.; De Vadder, F.; Arora, T.; Hallen, A.; Martens, E.; Björck, I.; Bäckhed, F. Dietary Fiber-Induced Improvement in Glucose Metabolism Is Associated with Increased Abundance of *Prevotella*. *Cell Metab.* 2015, 22, 971–982.
41. Turnbaugh, P.J.; Hamady, M.; Yatsunenko, T.; Cantarel, B.L.; Duncan, A.; Ley, R.E.; Sogin, M.L.; Jones, W.J.; Roe, B.A.; Affourtit, J.P.; et al. A core gut microbiome in obese and lean twins. *Nature* 2008, 457, 480–484.
42. Shapiro, H.; Suez, J.; Elinav, E. Personalized microbiome-based approaches to metabolic syndrome management and prevention. *J. Diabetes* 2017, 9, 226–236.
43. Vrieze, A.; Van Nood, E.; Holleman, F.; Salojärvi, J.; Kootte, R.S.; Bartelsman, J.F.; Dallinga-Thie, G.M.; Ackermans, M.T.; Serlie, M.J.; Oozeer, R.; et al. Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome. *Gastroenterology* 2012, 143, 913–916.e7.

44. Kadooka, Y.; Sato, M.; Imaizumi, K.; Ogawa, A.; Ikuyama, K.; Akai, Y.; Okano, M.; Kagoshima, M.; Tsuchida, T. Regulation of abdominal adiposity by probiotics (*Lactobacillus gasseri* SBT2055) in adults with obese tendencies in a randomized controlled trial. *Eur. J. Clin. Nutr.* 2010, **64**, 636–643.
45. Harsch, I.A.; Konturek, P.C. The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into “Old” Diseases. *Med Sci.* 2018, **6**, 32.
46. Canfora, E.; Jocken, J.W.; Blaak, E.E. Short-chain fatty acids in control of body weight and insulin sensitivity. *Nat. Rev. Endocrinol.* 2015, **11**, 577–591.
47. Rodriguez, J.; Hiel, S.; Delzenne, N.M. Metformin: Old friend, new ways of action-implication of the gut microbiome? *Curr. Opin. Clin. Nutr. Metab. Care* 2018, **21**, 294–301.
48. Karlsson, F.H.; Tremaroli, V.; Nookaew, I.; Bergström, G.; Behre, C.J.; Fagerberg, B.; Nielsen, J.; Bäckhed, F. Gut metagenome in European women with normal, impaired and diabetic glucose control. *Nature* 2013, **498**, 99–103.
49. Amar, J.; Lange, C.; Burcelin, R.; D.E.S.I.R. Study Group; Payros, G.; Garret, C.; Chabo, C.; Lantieri, O.; Courtney, M.; Marre, M.; et al. Blood Microbiota Dysbiosis Is Associated with the Onset of Cardiovascular Events in a Large General Population: The D.E.S.I.R. Study. *PLoS ONE* 2013, **8**, e54461.
50. Chen, X.; Devaraj, S. Gut Microbiome in Obesity, Metabolic Syndrome, and Diabetes. *Curr. Diabetes Rep.* 2018, **18**, 129.
51. Caruso, R.; Lo, B.C.; Núñez, G. Host–microbiota interactions in inflammatory bowel disease. *Nat. Rev. Immunol.* 2020, **20**, 411–426.
52. Nagao-Kitamoto, H.; Kitamoto, S.; Kuffa, P.; Kamada, N. Pathogenic role of the gut microbiota in gastrointestinal diseases. *Intest. Res.* 2016, **14**, 127–138.
53. Manichanh, C.; Borruel, N.; Casellas, F.; Guarner, F. The gut microbiota in IBD. *Nat. Rev. Gastroenterol. Hepatol.* 2012, **9**, 599–608.
54. Mukherjee, P.K.; Sendid, B.; Hoarau, G.; Colombel, J.-F.; Poulain, D.; Ghannoum, M.A. Mycobacteria in gastrointestinal diseases. *Nat. Rev. Gastroenterol. Hepatol.* 2015, **12**, 77–87.
55. Palm, N.W.; De Zoete, M.R.; Cullen, T.W.; Barry, N.A.; Stefanowski, J.; Hao, L.; Degnan, P.H.; Hu, J.; Peter, I.; Zhang, W.; et al. Immunoglobulin A Coating Identifies Colitogenic Bacteria in Inflammatory Bowel Disease. *Cell* 2014, **158**, 1000–1010.
56. Fakhoury, M.; Al-Salami, H.; Negruj, R.; Mooranian, A. Inflammatory bowel disease: Clinical aspects and treatments. *J. Inflamm. Res.* 2014, **7**, 113–120.
57. Ananthakrishnan, A.N. Epidemiology and risk factors for IBD. *Nat. Rev. Gastroenterol. Hepatol.* 2015, **12**, 205–217.
58. Shah, J.; Etienne, D.; Reddy, M.; Kothadia, J.P.; Shahidullah, A.; Baqui, A.A. Crohn's Disease Manifesting as a Duodenal Obstruction: An Unusual Case. *Gastroenterol. Res.* 2018, **11**, 436–440.
59. Frank, D.N.; Amand, A.L.S.; Feldman, R.A.; Boedeker, E.C.; Harpaz, N.; Pace, N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc. Natl. Acad. Sci. USA* 2007, **104**, 13780–13785.
60. Kamada, N.; Seo, S.-U.; Chen, G.Y.; Núñez, G. Role of the gut microbiota in immunity and inflammatory disease. *Nat. Rev. Immunol.* 2013, **13**, 321–335.
61. Hall, A.B.; Yassour, M.; Sauk, J.; Garner, A.; Jiang, X.; Arthur, T.; Lagoudas, G.K.; Vatanen, T.; Fornelos, N.; Wilson, R.; et al. A novel *Ruminococcus gnavus* clade enriched in inflammatory bowel disease patients. *Genome Med.* 2017, **9**, 1–12.
62. Caballero, S.; Pamer, E.G. Microbiota-Mediated Inflammation and Antimicrobial Defense in the Intestine. *Annu. Rev. Immunol.* 2015, **33**, 227–256.
63. Ahmed, I.; Roy, B.C.; Khan, S.A.; Septer, S.; Umar, S. Microbiome, Metabolome and Inflammatory Bowel Disease. *Microorganisms* 2016, **4**, 20.
64. Patel, T.; Bhattacharya, P.; Das, S. Gut microbiota: An Indicator to Gastrointestinal Tract Diseases. *J. Gastrointest. Cancer* 2016, **47**, 232–238.
65. Jeffery, I.; O'Toole, P.W.; Öhman, L.; Claesson, M.J.; Deane, J.; Quigley, E.M.M.; Simrén, M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. *Gut* 2011, **61**, 997–1006.
66. Parmar, A.S.; Alakulppi, N.; Paavola-Sakki, P.; Kurppa, K.; Halme, L.; Färkkilä, M.; Turunen, U.; Lappalainen, M.; Kontula, K.; Kaukinen, K.; et al. Association study of FUT2(rs601338) with celiac disease and inflammatory bowel disease in the Finnish population. *Tissue Antigens* 2012, **80**, 488–493.

67. Tong, M.; McHardy, I.; Ruegger, P.; Goudarzi, M.; Kashyap, P.C.; Haritunians, T.; Li, X.; Graeber, T.; Schwager, E.; Hutt enhower, C.; et al. Reprogramming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphis m. *ISME J.* 2014, 8, 2193–2206.
68. Chow, J.; Tang, H.; Mazmanian, S.K. Pathobionts of the gastrointestinal microbiota and inflammatory disease. *Curr. Opin. Immunol.* 2011, 23, 473–480.
69. Hourigan, S.K.; Chen, L.A.; Grigoryan, Z.; Laroche, G.; Weidner, M.; Sears, C.L.; Oliva-Hemker, M. Microbiome change s associated with sustained eradication of *Clostridium difficile* after single faecal microbiota transplantation in children w ith and without inflammatory bowel disease. *Aliment. Pharmacol. Ther.* 2015, 42, 741–752.
70. Singhvi, N.; Gupta, V.; Gaur, M.; Sharma, V.; Puri, A.; Singh, Y.; Dubey, G.P.; Lal, R. Interplay of Human Gut Microbiom e in Health and Wellness. *Indian J. Microbiol.* 2020, 60, 26–36.
71. Cryan, J.F.; Dinan, T.G. Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. *Nat. Rev. Neurosci.* 2012, 13, 701–712.
72. Frankiensztajn, L.M.; Elliott, E.; Koren, O. The microbiota and the hypothalamus-pituitary-adrenocortical (HPA) axis, im plications for anxiety and stress disorders. *Curr. Opin. Neurobiol.* 2020, 62, 76–82.
73. Sampson, T.R.; Mazmanian, S.K. Control of Brain Development, Function, and Behavior by the Microbiome. *Cell Host Microbe* 2015, 17, 565–576.
74. Gershon, M.D. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. *Curr. Opin. Endocrinol. Diabetes Obes.* 20 13, 20, 14–21.
75. Reigstad, C.S.; Salmonson, C.E.; Ili, J.F.R.; Szurszewski, J.H.; Linden, D.R.; Sonnenburg, J.L.; Farrugia, G.; Kashyap, P.C. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffi n cells. *FASEB J.* 2015, 29, 1395–1403.
76. Yano, J.M.; Yu, K.; Donaldson, G.P.; Shastri, G.G.; Ann, P.; Ma, L.; Nagler, C.R.; Ismagilov, R.F.; Mazmanian, S.K.; Hsi ao, E.Y. Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis. *Cell* 2015, 161, 264–276.
77. Braniste, V.; Al-Asmakh, M.; Kowal, C.; Anuar, F.; Abbaspour, A.; Tóth, M.; Korecka, A.; Bakocevic, N.; Ng, L.G.; Kundu, P.; et al. The gut microbiota influences blood-brain barrier permeability in mice. *Sci. Transl. Med.* 2014, 6, 263ra158.
78. Erny, D.; De Angelis, A.L.H.; Jaitin, D.; Wieghofer, P.; Staszewski, O.; David, E.; Keren-Shaul, H.; Mhlahloiv, T.; Jakobs hagen, K.; Buch, T.; et al. Host microbiota constantly control maturation and function of microglia in the CNS. *Nat. Neur osci.* 2015, 18, 965–977.
79. Bravo, J.A.; Forsythe, P.; Chew, M.V.; Escaravage, E.; Savignac, H.M.; Dinan, T.G.; Bienenstock, J.; Cryan, J.F. Ingesti on of *Lactobacillus* strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagu s nerve. *Proc. Natl. Acad. Sci. USA* 2011, 108, 16050–16055.
80. Forsythe, P.; Bienenstock, J.; Kunze, W.A. Vagal Pathways for Microbiome-Brain-Gut Axis Communication. In *Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease*; Lyte, M., Cryan, J.F., Eds.; *Advances in Experime ntal Medicine and Biology*; Springer: New York, NY, USA, 2014; Volume 817, pp. 115–133. ISBN 978-1-4939-0896-7.
81. Dantzer, R.; Konsman, J.-P.; Bluthé, R.-M.; Kelley, K.W. Neural and humoral pathways of communication from the imm une system to the brain: Parallel or convergent? *Auton. Neurosci.* 2000, 85, 60–65.
82. Fung, T.C.; Olson, C.A.; Hsiao, E.Y. Interactions between the microbiota, immune and nervous systems in health and di sease. *Nat. Neurosci.* 2017, 20, 145–155.
83. Du, Y.; Gao, X.-R.; Peng, L.; Ge, J.-F. Crosstalk between the microbiota-gut-brain axis and depression. *Heliyon* 2020, 6, e04097.
84. Dash, S.; Clarke, G.; Berk, M.; Jacka, F.N. The gut microbiome and diet in psychiatry: Focus on Depression. *Curr. Opin. Psychiatry* 2015, 28, 1–6.
85. Federico, A.; Dallio, M.; Caprio, G.G.; Ormando, V.M.; Loguercio, C. Gut microbiota and the liver. *Minerva Gastroentero l. Dietol.* 2017, 63, 385–398.
86. Braak, H.; de Vos, R.A.; Bohl, J.; Del Tredici, K. Gastric α -synuclein immunoreactive inclusions in Meissner's and Auerb ach's plexuses in cases staged for Parkinson's disease-related brain pathology. *Neurosci. Lett.* 2006, 396, 67–72.
87. Kiebertz, K.; Wunderle, K.B. Parkinson's disease: Evidence for environmental risk factors. *Mov. Disord.* 2012, 28, 8–13.
88. Savica, R.; Carlin, J.M.; Grossardt, B.; Bower, J.H.; Ahlskog, J.E.; Maraganore, D.M.; Bharucha, A.E.; Rocca, W.A. Med ical records documentation of constipation preceding Parkinson disease: A case-control study. *Neurology* 2009, 73, 175 2–1758.
89. Shannon, K.M.; Keshavarzian, A.; Dodiya, H.B.; Jakate, S.; Kordower, J.H. Is alpha-synuclein in the colon a biomarker f or premotor Parkinson's Disease? Evidence from 3 cases. *Mov. Disord.* 2012, 27, 716–719.

90. Scheperjans, F.; Aho, V.; Pereira, P.A.B.; Koskinen, K.; Paulin, L.; Pekkonen, E.; Haapaniemi, E.; Kaakkola, S.; Eerola-Rautio, J.; Pohja, M.; et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. *Mov. Disord.* 2015, 30, 350–358.
91. Niehaus, I. Endotoxin: Is it an environmental factor in the cause of Parkinson's disease? *Occup. Environ. Med.* 2003, 60, 378.
92. Guo, S.; Al-Sadi, R.; Said, H.M.; Ma, T.Y. Lipopolysaccharide Causes an Increase in Intestinal Tight Junction Permeability in Vitro and in Vivo by Inducing Enterocyte Membrane Expression and Localization of TLR-4 and CD14. *Am. J. Pathol.* 2013, 182, 375–387.
93. Tufekci, K.U.; Genc, S.; Genc, K. The Endotoxin-Induced Neuroinflammation Model of Parkinson's Disease. *Park. Dis.* 2011, 2011, 1–25.
94. Sarkar, S.R.; Banerjee, S. Gut microbiota in neurodegenerative disorders. *J. Neuroimmunol.* 2019, 328, 98–104.
95. Heneka, M.T.; Carson, M.J.; El Khoury, J.; Landreth, G.E.; Brosseron, F.; Feinstein, D.L.; Jacobs, A.H.; Wyss-Coray, T.; Vitorica, J.; Ransohoff, R.M.; et al. Neuroinflammation in Alzheimer's disease. *Lancet Neurol.* 2015, 14, 388–405.
96. Itzhaki, R.F.; Lathe, R.; Balin, B.J.; Ball, M.J.; Bearer, E.L.; Braak, H.; Bullido, M.J.; Carter, C.; Clerici, M.; Cosby, S.L.; et al. Microbes and Alzheimer's Disease. *J. Alzheimer's Dis.* 2016, 51, 979–984.
97. Ransohoff, R.M. How neuroinflammation contributes to neurodegeneration. *Science* 2016, 353, 777–783.
98. Cattaneo, A.; Cattane, N.; Galluzzi, S.; Provasi, S.; Lopizzo, N.; Festari, C.; Ferrari, C.; Guerra, U.P.; Paghera, B.; Muscio, C.; et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. *Neurobiol. Aging* 2017, 49, 60–68.
99. Liang, S.; Wang, T.; Hu, X.; Luo, J.; Li, W.; Wu, X.; Duan, Y.; Jin, F. Administration of *Lactobacillus helveticus* NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress. *Neuroscience* 2015, 310, 561–577.
100. Wang, I.-K.; Wu, Y.-Y.; Yang, Y.-F.; Ting, I.-W.; Lin, C.-C.; Yen, T.-H.; Chen, J.-H.; Wang, C.-H.; Huang, C.-C.; Lin, H.-C. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: A randomised, double-blind, placebo-controlled trial. *Benef. Microbes* 2015, 6, 423–430.
101. Akbari, E.; Asemi, Z.; Kakhaki, R.D.; Bahmani, F.; Kouchaki, E.; Tamtaji, O.R.; Hamidi, G.A.; Salami, M. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer's disease: A randomized, double-blind and controlled trial. *Front. Aging Neurosci.* 2016, 8, 256.
102. de Martel, C.; Ferlay, J.; Franceschi, S.; Vignat, J.; Bray, F.; Forman, D.; Plummer, M. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. *Lancet Oncol.* 2012, 13, 607–615.
103. Xuan, C.; Shamonki, J.M.; Chung, A.; DiNome, M.L.; Chung, M.; Sieling, P.A.; Lee, D.J. Microbial Dysbiosis Is Associated with Human Breast Cancer. *PLoS ONE* 2014, 9, e83744.
104. Arthur, J.C.; Perez-Chanona, E.; Mühlbauer, M.; Tomkovich, S.; Uronis, J.M.; Fan, T.-J.; Campbell, B.J.; Abujamel, T.; Dogan, B.; Rogers, A.B.; et al. Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota. *Science* 2012, 338, 120–123.
105. Bultman, S.J. Emerging roles of the microbiome in cancer. *Carcinogenesis* 2014, 35, 249–255.
106. Pai, R.; Tarnawski, A.S.; Tran, T. Deoxycholic Acid Activates β -Catenin Signaling Pathway and Increases Colon Cell Cancer Growth and Invasiveness. *Mol. Biol. Cell* 2004, 15, 2156–2163.
107. Cheng, K.; Raufman, J.-P. Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors. *Biochem. Pharmacol.* 2005, 70, 1035–1047.
108. Brown, J.R.; Dubois, R.N. COX-2: A Molecular Target for Colorectal Cancer Prevention. *J. Clin. Oncol.* 2005, 23, 2840–2855.
109. Shui, L.; Yang, X.; Li, J.; Yi, C.; Sun, Q.; Zhu, H. Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy. *Front. Immunol.* 2020, 10, 2989.
110. Round, J.L.; Mazmanian, S.K. Inducible Foxp3⁺ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. *Proc. Natl. Acad. Sci. USA* 2010, 107, 12204–12209.
111. Cebula, A.; Seweryn, M.; Rempala, G.A.; Pabla, S.S.; McIndoe, R.A.; Denning, T.L.; Bry, L.; Kraj, P.; Kisielow, P.; Ignatowicz, L. Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. *Nature* 2013, 497, 258–262.
112. Yi, M.; Jiao, D.; Qin, S.; Chu, Q.; Li, A.; Wu, K. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. *Integr. Cancer Ther.* 2019, 18, 153473541987635.

113. Wang, J.; Yang, H.-R.; Wang, D.-J.; Wang, X.-X. Association between the gut microbiota and patient responses to cancer immune checkpoint inhibitors (Review). *Oncol. Lett.* 2020, 20, 1.
114. Li, R.; Zhou, R.; Wang, H.; Li, W.; Pan, M.; Yao, X.; Zhan, W.; Yang, S.; Xu, L.; Ding, Y.; et al. Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer. *Cell Death Differ.* 2019, 26, 2447–2463.
115. Yu, L.-X.; Schwabe, L.-X.Y.R.F. The gut microbiome and liver cancer: Mechanisms and clinical translation. *Nat. Rev. Gastroenterol. Hepatol.* 2017, 14, 527–539.
116. Chen, D.; Wu, J.; Jin, D.; Wang, B.; Cao, H. Fecal microbiota transplantation in cancer management: Current status and perspectives. *Int. J. Cancer* 2019, 145, 2021–2031.
117. Mima, K.; Nishihara, R.; Qian, Z.R.; Cao, Y.; Sukawa, Y.; Nowak, J.A.; Yang, J.; Dou, R.; Masugi, Y.; Song, M.; et al. *Fusobacterium nucleatum* in colorectal carcinoma tissue and patient prognosis. *Gut* 2016, 65, 1973–1980.
118. Yang, Y.; Weng, W.; Peng, J.; Hong, L.; Yang, L.; Toiyama, Y.; Gao, R.; Liu, M.; Yin, M.; Pan, C.; et al. *Fusobacterium nucleatum* Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor- κ B, and Up-regulating Expression of MicroRNA-21. *Gastroenterology* 2017, 152, 851–866.e24.
119. Chung, L.; Orberg, E.T.; Geis, A.L.; Chan, J.L.; Fu, K.; Shields, C.E.; Dejea, C.M.; Fathi, P.; Chen, J.; Finard, B.B.; et al. *Bacteroides fragilis* Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. *Cell Host Microbe* 2018, 23, 203–214.
120. Long, X.; Wong, C.C.; Tong, L.; Chu, E.S.H.; Szeto, C.H.; Go, M.Y.Y.; Coker, O.O.; Chan, A.W.H.; Chan, F.K.L.; Sung, J.J.Y.; et al. *Peptostreptococcus anaerobius* promotes colorectal carcinogenesis and modulates tumour immunity. *Nat. Microbiol.* 2019, 4, 2319–2330.
121. Rubinstein, M.R.; Wang, X.; Liu, W.; Hao, Y.; Cai, G.; Han, Y.W. *Fusobacterium nucleatum* Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/ β -Catenin Signaling via its FadA Adhesin. *Cell Host Microbe* 2013, 14, 195–206.
122. Fiorentini, C.; Carlini, F.; Germinario, E.A.P.; Maroccia, Z.; Travaglione, S.; Fabbri, A. Gut Microbiota and Colon Cancer: A Role for Bacterial Protein Toxins? *Int. J. Mol. Sci.* 2020, 21, 6201.
123. Candela, M. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. *World J. Gastroenterol.* 2014, 20, 908–922.
124. Amrutkar, M.; Gladhaug, I.P. Pancreatic Cancer Chemoresistance to Gemcitabine. *Cancers* 2017, 9, 157.
125. Akshintala, V.S.; Talukdar, R.; Singh, V.K.; Goggins, M. The Gut Microbiome in Pancreatic Disease. *Clin. Gastroenterol. Hepatol.* 2019, 17, 290–295.
126. Zhang, S.; Yang, Y.; Weng, W.; Guo, B.; Cai, G.; Ma, Y.; Cai, S. *Fusobacterium nucleatum* promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. *J. Exp. Clin. Cancer Res.* 2019, 38, 1–13.
127. Panebianco, C.; Adamberg, K.; Jaagura, M.; Copetti, M.; Fontana, A.; Adamberg, S.; Kolk, K.; Vilu, R.; Andriulli, A.; Paziienza, V. Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice. *Cancer Chemother. Pharmacol.* 2018, 81, 773–782.
128. Mei, Q.-X.; Huang, C.-L.; Luo, S.-Z.; Zhang, X.-M.; Zeng, Y.; Lu, Y.-Y. Characterization of the duodenal bacterial microbiota in patients with pancreatic head cancer vs. healthy controls. *Pancreatol.* 2018, 18, 438–445.
129. Heikkilä, P.; But, A.; Sorsa, T.; Haukka, J. Periodontitis and cancer mortality: Register-based cohort study of 68,273 adults in 10-year follow-up. *Int. J. Cancer* 2018, 142, 2244–2253.
130. Niess, J.H.; Reinecker, H.-C. Dendritic cells in the recognition of intestinal microbiota. *Cell. Microbiol.* 2006, 8, 558–564.
131. Zhang, X.; Liu, Q.; Liao, Q.; Zhao, Y. Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy. *J. Cancer* 2020, 11, 2749–2758.
132. Viale, R.P.H. The American Cancer Society's Facts & Figures: 2020 Edition. *J. Adv. Pract. Oncol.* 2020, 11, 135–136.
133. Van Gemert, W.A.; Lanting, C.I.; Goldbohm, R.A.; van den Brandt, P.A.; Groeters, H.G.; Kampman, E.; Kiemeneij, L.A.; van Leeuwen, F.E.; Monninkhof, E.M.; de Vries, E.; et al. The proportion of postmenopausal breast cancer cases in the Netherlands attributable to lifestyle-related risk factors. *Breast Cancer Res. Treat.* 2015, 152, 155–162.
134. Luu, T.H.; Michel, C.; Bard, J.-M.; Dravet, F.; Nazih, H.; Bobin-Dubigeon, C. Intestinal Proportion of *Blautia* sp. is Associated with Clinical Stage and Histoprognostic Grade in Patients with Early-Stage Breast Cancer. *Nutr. Cancer* 2017, 69, 267–275.
135. Frugé, A.D.; Van Der Pol, W.; Rogers, L.Q.; Morrow, C.D.; Tsuruta, Y.; Demark-Wahnefried, W. Fecal *Akkermansia muciniphila* Is Associated with Body Composition and Microbiota Diversity in Overweight and Obese Women with Breast Cancer. *Cell Host Microbe* 2020, 27, 100–111.e10.

136. Laborda-Illanes, A.; Sanchez-Alcoholado, L.; Dominguez-Recio, M.E.; Jimenez-Rodriguez, B.; Lavado, R.; Comino-Méndez, I.; Alba, E.; Queipo-Ortuño, M.I. Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment. *Cancers* 2020, 12, 2465.
137. Goedert, J.J.; Jones, G.; Hua, X.; Xu, X.; Yu, G.; Flores, R.; Falk, R.T.; Gail, M.H.; Shi, J.; Ravel, J.; et al. Investigation of the Association Between the Fecal Microbiota and Breast Cancer in Postmenopausal Women: A Population-Based Case-Control Pilot Study. *JNCI J. Natl. Cancer Inst.* 2015, 107.
138. Zhu, J.; Liao, M.; Yao, Z.; Liang, W.; Li, Q.; Liu, J.; Yang, H.; Ji, Y.; Wei, W.; Tan, A.; et al. Breast cancer in postmenopausal women is associated with an altered gut metagenome. *Microbiome* 2018, 6, 1–13.
139. Engstrand, L.; Graham, D.Y. Microbiome and Gastric Cancer. *Dig. Dis. Sci.* 2020, 65, 865–873.
140. Graham, D.Y. *Helicobacter pylori* Update: Gastric Cancer, Reliable Therapy, and Possible Benefits. *Gastroenterology* 2015, 148, 719–731.
141. Miftahussurur, M.; Yamaoka, Y.; Graham, D.Y. *Helicobacter pylori* as an oncogenic pathogen, revisited. *Expert Rev. Mol. Med.* 2017, 19, e4.
142. Rakoff-Nahoum, S.; Medzhitov, R. Toll-like receptors and cancer. *Nat. Rev. Cancer* 2008, 9, 57–63.
143. Suzuki, M.; Miura, S.; Mori, M.; Kai, A.; Suzuki, H.; Fukumura, D.; Suematsu, M.; Tsuchiya, M. Rebamipide, a novel anti ulcer agent, attenuates *Helicobacter pylori* induced gastric mucosal cell injury associated with neutrophil derived oxidants. *Gut* 1994, 35, 1375–1378.
144. Feig, D.I.; Reid, T.M.; Loeb, L.A. Reactive oxygen species in tumorigenesis. *Cancer Res.* 1994, 54, 1890–1894.
145. D’Angio, C.T.; Finkelstein, J.N. Oxygen Regulation of Gene Expression: A Study in Opposites. *Mol. Genet. Metab.* 2000, 71, 371–380.
146. Hartung, M.L.; Gruber, D.C.; Koch, K.N.; Grüter, L.; Rehrauer, H.; Tegtmeyer, N.; Backert, S.; Müller, A.H. *pylori* -Induced DNA Strand Breaks Are Introduced by Nucleotide Excision Repair Endonucleases and Promote NF- κ B Target Gene Expression. *Cell Rep.* 2015, 13, 70–79.
147. Hanada, K.; Graham, D.Y. *Helicobacter pylori* and the molecular pathogenesis of intestinal-type gastric carcinoma. *Expert Rev. Anticancer. Ther.* 2014, 14, 947–954.
148. Eun, C.S.; Kim, B.K.; Han, D.S.; Kim, S.Y.; Kim, K.M.; Choi, B.Y.; Song, K.S.; Kim, Y.S.; Kim, J.F. Differences in Gastric Mucosal Microbiota Profiling in Patients with Chronic Gastritis, Intestinal Metaplasia, and Gastric Cancer Using Pyrosequencing Methods. *Helicobacter* 2014, 19, 407–416.
149. Wang, C.; Weber, A.; Graham, D.Y. Age, Period, and Cohort Effects on Gastric Cancer Mortality. *Dig. Dis. Sci.* 2014, 60, 514–523.
150. Li, T.H.; Qin, Y.; Sham, P.C.; Lau, K.; Chu, K.-M.; Leung, W.K. Alterations in Gastric Microbiota After H. *Pylori* Eradication and in Different Histological Stages of Gastric Carcinogenesis. *Sci. Rep.* 2017, 7, 44935.
151. Coker, O.O.; Dai, Z.; Nie, Y.; Zhao, G.; Cao, L.; Nakatsu, G.; Wu, W.K.; Wong, S.H.; Chen, Z.; Sung, J.J.Y.; et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. *Gut* 2018, 67, 1024–1032.
152. Dehhaghi, M.; Panahi, H.K.S.; Heng, B.; Guillemin, G.J. The Gut Microbiota, Kynurenine Pathway, and Immune System Interaction in the Development of Brain Cancer. *Front. Cell Dev. Biol.* 2020, 8, 562812.
153. Adams, S.; Braid, N.; Bessesde, A.; Brew, B.J.; Grant, R.; Teo, C.; Guillemin, G.J. The Kynurenine Pathway in Brain Tumor Pathogenesis. *Cancer Res.* 2012, 72, 5649–5657.
154. Platten, M.; Nollen, E.A.A.; Röhrig, U.F.; Fallarino, F.; Opitz, C.A. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. *Nat. Rev. Drug Discov.* 2019, 18, 379–401.
155. Jin, C.; Lagoudas, G.K.; Zhao, C.; Bullman, S.; Bhutkar, A.; Hu, B.; Ameh, S.; Sandel, D.; Liang, X.S.; Mazzilli, S.; et al. Commensal microbiota promote lung cancer development via $\gamma\delta$ T cells. *Cell* 2019, 176, 998–1013.
156. Schalper, K.A.; Carvajal-Hausdorf, D.; McLaughlin, J.; Altan, M.; Velcheti, V.; Gaule, P.; Sanmamed, M.F.; Chen, L.; Herbst, R.S.; Rimm, D.L. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. *Clin. Cancer Res.* 2017, 23, 370–378.
157. Kaur, H.; Bose, C.; Mande, S.S. Tryptophan Metabolism by Gut Microbiome and Gut-Brain-Axis: An in silico Analysis. *Front. Neurosci.* 2019, 13, 1365.
158. Roesch, S.; Rapp, C.; Dettling, S.; Herold-Mende, C. When Immune Cells Turn Bad—Tumor-Associated Microglia/Macrophages in Glioma. *Int. J. Mol. Sci.* 2018, 19, 436.

159. Martin-Gallausiaux, C.; Larraufie, P.; Jarry, A.; Béguet-Crespel, F.; Marinelli, L.; LeDue, F.; Reimann, F.; Blottière, H.M.; Lapaque, N. Butyrate Produced by Commensal Bacteria Down-Regulates Indolamine 2,3-Dioxygenase 1 (IDO-1) Expression via a Dual Mechanism in Human Intestinal Epithelial Cells. *Front. Immunol.* 2018, 9, 2838.
160. Mehrian-Shai, R.; Reichardt, J.K.; Harris, C.C.; Toren, A. The Gut–Brain Axis, Paving the Way to Brain Cancer. *Trends Cancer* 2019, 5, 200–207.
161. David, L.A.; Maurice, C.F.; Carmody, R.N.; Gootenberg, D.; Button, J.E.; Wolfe, B.E.; Ling, A.V.; Devlin, A.S.; Varma, Y.; Fischbach, M.; et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature* 2014, 505, 559–563.
162. Oriach, C.S.; Robertson, R.C.; Stanton, C.; Cryan, J.F.; Dinan, T.G. Food for thought: The role of nutrition in the microbiota-gut–brain axis. *Clin. Nutr. Exp.* 2016, 6, 25–38.
163. Hussey, S.; Bergman, M. *Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms*; Elsevier: Oxford, UK, 2014; *The Gut Microbiota and Effects on Metabolism*; ISBN 978-0-12-386457-4.
164. Rogers, T.E.; Pudlo, N.A.; Koropatkin, N.M.; Bell, J.S.K.; Balasch, M.M.; Jasker, K.; Martens, E.C. Dynamic responses of *Bacteroides thetaiotaomicron* during growth on glycan mixtures. *Mol. Microbiol.* 2013, 88, 876–890.
165. Larsbrink, J.; Rogers, T.E.; Hemsworth, G.R.; McKee, L.S.; Tauzin, A.S.; Spadiut, O.; Klintner, S.; Pudlo, N.A.; Urs, K.; Koropatkin, N.M.; et al. A discrete genetic locus confers xyloglucan metabolism in select human gut *Bacteroidetes*. *Nature* 2014, 506, 498–502.
166. Marcobal, A.; Barboza, M.; Sonnenburg, E.D.; Pudlo, N.; Martens, E.C.; Desai, P.; Lebrilla, C.B.; Weimer, B.C.; Mills, D.A.; German, J.B.; et al. *Bacteroides* in the Infant Gut Consume Milk Oligosaccharides via Mucus-Utilization Pathways. *Cell Host Microbe* 2011, 10, 507–514.
167. Walsh, C.J.; Guinane, C.M.; O'Toole, P.W.; Cotter, P.D. Beneficial modulation of the gut microbiota. *FEBS Lett.* 2014, 588, 4120–4130.
168. Macfarlane, G.T.; Macfarlane, S. Bacteria, Colonic Fermentation, and Gastrointestinal Health. *J. AOAC Int.* 2012, 95, 50–60.
169. Peredo-Lovillo, A.; Romero-Luna, H.; Jiménez-Fernández, M. Health promoting microbial metabolites produced by gut microbiota after prebiotics metabolism. *Food Res. Int.* 2020, 136, 109473.
170. Ley, R.E.; Bäckhed, F.; Turnbaugh, P.; Lozupone, C.A.; Knight, R.D.; Gordon, J.I. Obesity alters gut microbial ecology. *Proc. Natl. Acad. Sci. USA* 2005, 102, 11070–11075.
171. Turnbaugh, P.J.; Bäckhed, F.; Fulton, L.; Gordon, J.I. Diet-Induced Obesity Is Linked to Marked but Reversible Alterations in the Mouse Distal Gut Microbiome. *Cell Host Microbe* 2008, 3, 213–223.
172. Wu, G.D.; Chen, J.; Hoffmann, C.; Bittinger, K.; Chen, Y.Y.; Keilbaugh, S.A.; Bewtra, M.; Knights, D.; Walters, W.A.; Knight, R.; et al. Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes. *Science* 2011, 334, 105–108.
173. Shen, W.; Gaskins, H.R.; McIntosh, M.K. Influence of dietary fat on intestinal microbes, inflammation, barrier function and metabolic outcomes. *J. Nutr. Biochem.* 2014, 25, 270–280.
174. Müller, M.; Canfora, E.E.; Blaak, E.E. Gastrointestinal Transit Time, Glucose Homeostasis and Metabolic Health: Modulation by Dietary Fibers. *Nutrients* 2018, 10, 275.
175. Sprong, R.; Schonewille, A.; Van Der Meer, R. Dietary cheese whey protein protects rats against mild dextran sulfate sodium-induced colitis: Role of mucin and microbiota. *J. Dairy Sci.* 2010, 93, 1364–1371.
176. Matijašić, B.B.; Obermajer, T.; Lipoglavšek, L.; Grabnar, I.; Avguštin, G.; Rogelj, I. Association of dietary type with fecal microbiota in vegetarians and omnivores in Slovenia. *Eur. J. Nutr.* 2013, 53, 1051–1064.
177. Delzenne, N.M.; Neyrinck, A.M.; Cani, P.D. Modulation of the gut microbiota by nutrients with prebiotic properties: Consequences for host health in the context of obesity and metabolic syndrome. *Microb. Cell Factories* 2011, 10, S10.
178. Quigley, E.M. Prebiotics and Probiotics in Digestive Health. *Clin. Gastroenterol. Hepatol.* 2019, 17, 333–344.
179. Azad, M.A.K.; Sarker, M.; Li, T.; Yin, J. Probiotic Species in the Modulation of Gut Microbiota: An Overview. *BioMed Res. Int.* 2018, 2018, 1–8.
180. Zendeboodi, F.; Khorshidian, N.; Mortazavian, A.M.; da Cruz, A.G. Probiotic: Conceptualization from a new approach. *Curr. Opin. Food Sci.* 2020, 32, 103–123.
181. Markowiak-Kopeć, P.; Śliżewska, K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. *Nutrients* 2017, 9, 1021.
182. Schachtsiek, M.; Hammes, W.P.; Hertel, C. Characterization of *Lactobacillus coryniformis* DSM 20001T Surface Protein Cpf Mediating Coaggregation with and Aggregation among Pathogens. *Appl. Environ. Microbiol.* 2004, 70, 7078–7085.

183. Brandão, R.L.; Castro, I.M.; Bambirra, E.A.; Amaral, S.C.; Fietto, L.G.; Tropia, M.J.M.; Neves, M.J.; Dos Santos, R.G.; Gomes, N.; Nicoli, J.R. Intracellular Signal Triggered by Cholera Toxin in *Saccharomyces boulardii* and *Saccharomyces cerevisiae*. *Appl. Environ. Microbiol.* 1998, 64, 564–568.
184. Isolauri, E.; Sütas, Y.; Kankaanpää, P.; Arvilommi, H.; Salminen, S. Probiotics: Effects on immunity. *Am. J. Clin. Nutr.* 2001, 73, 444s–450s.
185. Arthur, J.; Gharaibeh, R.Z.; Uronis, J.M.; Perez-Chanona, E.; Sha, W.; Tomkovich, S.; Mühlbauer, M.; Fodor, A.A.; Jobin, C. VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer. *Sci. Rep.* 2013, 3, 2868.
186. Sugahara, H.; Odamaki, T.; Fukuda, S.; Kato, T.; Xiao, J.-Z.; Abe, F.; Kikuchi, J.; Ohno, H. Probiotic *Bifidobacterium longum* alters gut luminal metabolism through modification of the gut microbial community. *Sci. Rep.* 2015, 5, 13548.
187. Turroni, F.; Milani, C.; Duranti, S.; Mancabelli, L.; Mangifesta, M.; Viappiani, A.; Lugli, G.A.; Ferrario, C.; Gioiosa, L.; Ferrarini, A.; et al. Deciphering bifidobacterial-mediated metabolic interactions and their impact on gut microbiota by a multi-omics approach. *ISME J.* 2016, 10, 1656–1668.
188. Park, D.-Y.; Ahn, Y.-T.; Park, S.-H.; Huh, C.-S.; Yoo, S.-R.; Yu, R.; Sung, M.-K.; McGregor, R.A.; Choi, M.-S. Supplementation of *Lactobacillus curvatus* HY7601 and *Lactobacillus plantarum* KY1032 in Diet-Induced Obese Mice Is Associated with Gut Microbial Changes and Reduction in Obesity. *PLoS ONE* 2013, 8, e59470.
189. Sánchez, B.; Delgado, S.; Blanco-Míguez, A.; Lourenço, A.; Gueimonde, M.; Margolles, A. Probiotics, gut microbiota, and their influence on host health and disease. *Mol. Nutr. Food Res.* 2017, 61, 1600240.
190. Larsen, N.; Vogensen, F.K.; Gøbel, R.J.; Michaelsen, K.F.; Forssten, S.D.; Lahtinen, S.J.; Jakobsen, M. Effect of *Lactobacillus salivarius* Ls-33 on fecal microbiota in obese adolescents. *Clin. Nutr.* 2013, 32, 935–940.
191. Veiga, P.; Pons, N.; Agrawal, A.; Oozeer, R.; Guyonnet, D.; Brazeilles, R.; Faurie, J.M.; van Hylckama Vlieg, J.E.; Houghton, L.A.; Whorwell, P.J.; et al. Changes of the human gut microbiome induced by a fermented milk product. *Sci. Rep.* 2015, 4, 6328.
192. Lyra, A.; Krogius-Kurikka, L.; Nikkilä, J.; Malinen, E.; Kajander, K.; Kurikka, K.; Korpela, R.; Palva, A. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. *BMC Gastroenterol.* 2010, 10, 110.
193. Sánchez, B.; Noriega, L.; Ruas-Madiedo, P.; de los Reyes-Gavilán, C.G.; Margolles, A. Acquired resistance to bile increases fructose-6-phosphate phosphoketolase activity in *Bifidobacterium*. *FEMS Microbiol. Lett.* 2004, 235, 35–41.
194. Egan, M.; Motherway, M.O.; Kilcoyne, M.; Kane, M.; Joshi, L.; Ventura, M.; Van Sinderen, D. Cross-feeding by *Bifidobacterium breve* UCC2003 during co-cultivation with *Bifidobacterium bifidum* PRL2010 in a mucin-based medium. *BMC Microbiol.* 2014, 14, 1–14.
195. Egan, M.; Motherway, M.O.; Ventura, M.; Van Sinderen, D. Metabolism of Sialic Acid by *Bifidobacterium breve* UCC2003. *Appl. Environ. Microbiol.* 2014, 80, 4414–4426.
196. Kristensen, N.B.; Bryrup, T.; Allin, K.H.; Nielsen, T.; Hansen, T.H.; Pedersen, O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: A systematic review of randomized controlled trials. *Genome Med.* 2016, 8, 1–11.
197. Naito, Y.; Uchiyama, K.; Takagi, T. A next-generation beneficial microbe: *Akkermansia muciniphila*. *J. Clin. Biochem. Nutr.* 2018, 63, 33–35.
198. Shin, N.-R.; Lee, J.-C.; Lee, H.-Y.; Kim, M.-S.; Whon, T.W.; Lee, M.-S.; Bae, J.-W. An increase in the *Akkermansia* spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. *Gut* 2013, 63, 727–735.
199. Routy, B.; Le Chatelier, E.; DeRosa, L.; Duong, C.P.M.; Alou, M.T.; Daillère, R.; Fluckiger, A.; Messaoudene, M.; Rauber, C.; Roberti, M.P.; et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. *Science* 2018, 359, 91–97.
200. Hou, Q.; Zhao, F.; Liu, W.; Lv, R.; Khine, W.W.; Han, J.; Sun, Z.; Lee, Y.-K.; Zhang, H. Probiotic-directed modulation of gut microbiota is basal microbiome dependent. *Gut Microbes* 2020, 12, 1736974.
201. Hibberd, A.; Yde, C.; Ziegler, M.; Honoré, A.; Saarinen, M.; Lahtinen, S.; Stahl, B.; Jensen, H.; Stenman, L. Probiotic or synbiotic alters the gut microbiota and metabolism in a randomised controlled trial of weight management in overweight adults. *Benef. Microbes* 2019, 10, 121–135.
202. Canello, R.; Turroni, S.; Rampelli, S.; Cattaldo, S.; Candela, M.; Cattani, L.; Mai, S.; Vietti, R.; Scacchi, M.; Brigidi, P.; et al. Effect of Short-Term Dietary Intervention and Probiotic Mix Supplementation on the Gut Microbiota of Elderly Obese Women. *Nutrients* 2019, 11, 3011.

203. Terpou, A.; Papadaki, A.; Lappa, I.K.; Kachrimanidou, V.; Bosnea, L.A.; Kopsahelis, N. Probiotics in Food Systems: Significance and Emerging Strategies Towards Improved Viability and Delivery of Enhanced Beneficial Value. *Nutrients* 2019, 11, 1591.
204. Gibson, G.R.; Hutkins, R.; Sanders, M.E.; Prescott, S.L.; Reimer, R.A.; Salminen, S.J.; Scott, K.; Stanton, C.; Swanson, K.S.; Cani, P.D.; et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat. Rev. Gastroenterol. Hepatol.* 2017, 14, 491–502.
205. Roberfroid, M.; Gibson, G.R.; Hoyles, L.; McCartney, A.L.; Rastall, R.; Rowland, I.; Wolvers, D.; Watzl, B.; Szajewska, H.; Stahl, B.; et al. Prebiotic effects: Metabolic and health benefits. *Br. J. Nutr.* 2010, 104, S1–S63.
206. Al-Sheraji, S.H.; Ismail, A.; Manap, M.Y.; Mustafa, S.; Yusof, R.M.; Hassan, F.A. Prebiotics as functional foods: A review. *J. Funct. Foods* 2013, 5, 1542–1553.
207. Davani-Davari, D.; Negahdaripour, M.; Karimzadeh, I.; Seifan, M.; Mohkam, M.; Masoumi, S.J.; Berenjian, A.; Ghasemi, Y. Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications. *Foods* 2019, 8, 92.
208. Besten, G.D.; van Eunen, K.; Groen, A.K.; Venema, K.; Reijngoud, D.-J.; Bakker, B.M. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J. Lipid Res.* 2013, 54, 2325–2340.
209. Tan, J.; McKenzie, C.; Potamitis, M.; Thorburn, A.N.; Mackay, C.R.; Macia, L. The Role of Short-Chain Fatty Acids in Health and Disease. In *Advances in Immunology*; Elsevier: Oxford, UK, 2014; Volume 121, pp. 91–119. ISBN 978-0-12-801000-4.
210. Dalile, B.; Verbeke, K.; Van Oudenhove, L.; Vervliet, B. Nourishing the gut microbiota: The potential of prebiotics in microbiota-gut-brain axis research. *Behav. Brain Sci.* 2019, 42, 69.
211. Ansell, J.; Parkar, S.; Paturi, G.; Rosendale, D.; Blatchford, P. Modification of the Colonic Microbiota. In *Advances in Food and Nutrition Research*; Elsevier: Oxford, UK, 2013; Volume 68, pp. 205–217. ISBN 978-0-12-394294-4.
212. So, D.; Whelan, K.; Rossi, M.; Morrison, M.; Holtmann, G.; Kelly, J.T.; Shanahan, E.R.; Staudacher, H.; Campbell, K.L. Dietary fiber intervention on gut microbiota composition in healthy adults: A systematic review and meta-analysis. *Am. J. Clin. Nutr.* 2018, 107, 965–983.
213. Everard, A.; Lazarevic, V.; Gaïa, N.; Johansson, M.; Ståhlman, M.; Backhed, F.; Delzenne, N.; Schrenzel, J.; François, P.; Cani, P. Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. *ISME J.* 2014, 8, 2116–2130.
214. Holscher, H.D.; Caporaso, J.G.; Hooda, S.; Brulc, J.M.; Fahey, G.C.; Swanson, K. Fiber supplementation influences phylogenetic structure and functional capacity of the human intestinal microbiome: Follow-up of a randomized controlled trial. *Am. J. Clin. Nutr.* 2014, 101, 55–64.
215. Vandeputte, D.; Falony, G.; Vieira-Silva, S.; Wang, J.; Sailer, M.; Theis, S.; Verbeke, K.; Raes, J. Prebiotic inulin-type fructans induce specific changes in the human gut microbiota. *Gut* 2017, 66, 1968–1974.
216. Falony, G.; Joossens, M.; Vieira-Silva, S.; Wang, J.; Darzi, Y.; Faust, K.; Kurilshikov, A.; Bonder, M.J.; Valles-Colomer, M.; Vandeputte, D.; et al. Population-level analysis of gut microbiome variation. *Science* 2016, 352, 560–564.
217. Bindels, L.B.; Walter, J.; Ramer-Tait, A.E. Resistant starches for the management of metabolic diseases. *Curr. Opin. Clin. Nutr. Metab. Care* 2015, 18, 559–565.
218. Flint, H.J. The impact of nutrition on the human microbiome. *Nutr. Rev.* 2012, 70, S10–S13.
219. Martínez, I.; Kim, J.; Duffy, P.R.; Schlegel, V.L.; Walter, J. Resistant Starches Types 2 and 4 Have Differential Effects on the Composition of the Fecal Microbiota in Human Subjects. *PLoS ONE* 2010, 5, e15046.
220. Tachon, S.; Zhou, J.; Keenan, M.; Martin, R.; Marco, M.L. The intestinal microbiota in aged mice is modulated by dietary resistant starch and correlated with improvements in host responses. *FEMS Microbiol. Ecol.* 2012, 83, 299–309.
221. Umu, Ö.C.; Frank, J.A.; Fangel, J.U.; Oostindjer, M.; da Silva, C.S.; Bolhuis, E.J.; Bosch, G.; Willats, W.G.; Pope, P.B.; Diep, D.B. Resistant starch diet induces change in the swine microbiome and a predominance of beneficial bacterial populations. *Microbiome* 2015, 3, 1–15.
222. Fehlbaum, S.; Prudence, K.; Kieboom, J.; Heerikhuisen, M.; Broek, T.V.D.; Schuren, F.H.J.; Steinert, R.E.; Raederstorff, D. In Vitro Fermentation of Selected Prebiotics and Their Effects on the Composition and Activity of the Adult Gut Microbiota. *Int. J. Mol. Sci.* 2018, 19, 3097.
223. Jakobsen, L.M.A.; Maldonado-Gómez, M.X.; Sundekilde, U.K.; Andersen, H.J.; Nielsen, D.S.; Bertram, H.C. Metabolic Effects of Bovine Milk Oligosaccharides on Selected Commensals of the Infant Microbiome—Commensalism and Postbiotic Effects. *Metabolites* 2020, 10, 167.

224. Tran, T.T.T.; Cousin, F.J.; Lynch, D.B.; Menon, R.; Brulc, J.; Brown, J.R.-M.; O'Herlihy, E.; Butto, L.F.; Power, K.; Jeffery, I.; et al. Prebiotic supplementation in frail older people affects specific gut microbiota taxa but not global diversity. *Microbiome* 2019, 7, 1–17.
225. Halmos, E.; Christophersen, C.T.; Bird, A.R.; Shepherd, S.J.; Muir, J.G.; Gibson, P.R. Consistent Prebiotic Effect on Gut Microbiota with Altered FODMAP Intake in Patients with Crohn's Disease: A Randomised, Controlled Cross-Over Trial of Well-Defined Diets. *Clin. Transl. Gastroenterol.* 2016, 7, e164.
226. Vandeputte, D.; Joossens, M. Effects of Low and High FODMAP Diets on Human Gastrointestinal Microbiota Composition in Adults with Intestinal Diseases: A Systematic Review. *Microorganisms* 2020, 8, 1638.

Retrieved from <https://encyclopedia.pub/entry/history/show/25772>